[1] |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.e8.
|
[2] |
Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease[J]. Circulation, 2020, 141(20):1648-1655.
|
[3] |
Zhai Z, Li C, Chen Y, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines[J]. Thromb Haemost, 2020, 120(6):937-948.
|
[4] |
Elbaz-Greener G, Masih S, Fang J, et al. Temporal trends and clinical consequences of wait times for transcatheter aortic valve replacement: a population-based study[J]. Circulation, 2018, 138(5):483-493.
|
[5] |
Ro R, Khera S, Tang G, et al. Characteristics and outcomes of patients deferred for transcatheter aortic valve replacement because of COVID-19[J]. JAMA Netw Open, 2020, 3(9):e2019801.
|
[6] |
Giacomin E, Barioli A, Favero L, et al. Safety and feasibility of transcatheter aortic valve replacement in COVID-19 patients: a case series[J]. Cardiovasc Revasc Med, 2021, 28S:68-71.
|
[7] |
Bauernschmitt R, Gabriel P, Gottardi R, et al. Valve-in-valve transcatheter aortic valve replacement in a young patient with a suspected COVID-19 infection: A surgical dilemma in the era of the COVID-19 pandemic[J]. Eur J Cardiothorac Surg, 2020, 58(1):188-189.
|
[8] |
中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国医药, 2022, 17(4):481-487.
|
[9] |
Shah PB, Welt F, Mahmud E, et al. Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: An ACC/SCAI position statement[J]. JACC Cardiovasc Interv, 2020, 13(12):1484-1488.
|
[10] |
Banerjee S, Tarantini G, Abu-Fadel M, et al. Coronavirus disease 2019 catheterization laboratory survey[J]. J Am Heart Assoc, 2020, 9(15):e017175.
|
[11] |
Tarantini G, Nai Fovino L, Scotti A, et al. [Impact of COVID-19 pandemic on structural heart interventions in Italy][J]. G Ital Cardiol (Rome), 2020, 21(11 Suppl 1):45S-47S.
|
[12] |
Faroux L, Chen S, Muntané-Carol G, et al. Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis[J]. Eur Heart J, 2020, 41(29):2771-2781.
|
[13] |
Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry[J]. JACC Cardiovasc Interv, 2016, 9(21):2189-2199.
|
[14] |
Kapadia SR, Wazni O, Krishnaswamy A. pacemaker implantation after TAVR[J]. JACC Cardiovasc Imaging, 2017, 10(10 Pt A):1148-1150.
|
[15] |
Eschenbach LK, Erlebach M, Deutsch MA, et al. Stroke after transcatheter aortic valve replacement: a severe complication with low predictability[J]. Catheter Cardiovasc Interv, 2022, 99(6):1897-1905.
|